RE:RE:RE:Ceapro % Ownership Hey Ciao,
I've been around before the days of Dr. Redmond and seen the company trading at .01 and at 2.28. In the past, I had older usernames, but I let them lapped mainly due to forgetting the passwords.
Regarding voicing my option, I don't have much to add to the re-occurring themes:
- The company comms are lacking. I can contribute this to Gilles not being a pumper and takes a very conservative approach. They can do better with their comms regarding progression on efforts and transparency—for example, the functional drink.
- Jenene isn't very fruitful in creating investor interest. I have been at AGMs where Gilles said she was ready to promote, but he held her back by wanted more evidence before doing so, which ties into not a pumper and very conservative. The question is, are they getting value for their dollar?
- Responsive of IR, at times, Jenene has gotten back to me, and other times she hasn't. When I reached out, I asked for clarification on publicly release information only.
- The general frustration with the speed of progression of their pipelines. I do believe they are building a business using a conservative approach. They are trying to protect their cash flow to ensure that they can reach their goals without being placed in a precarious situation.
- ISA is a tiny bit bitter but raises some valid points amongst his ramblings
- etc.
I believe the company has never been in a better position and looking for results in the near future (2021) as it seems like they have all the pieces in place. However, there are still hurdles, ie. getting scalable production in place, finalizing the right deals, cholesterol trials yielding positive results. It is also encouraging that they can use new low-cost delivery system to deliver active ingredients. I believed this was the main barrier to their functional drink deal, as beta-glucan was too expensive for a mass commercial drink.
Let's see what 2021 brings and GLTA.